Want to see ACXP full AI Analyst Report?
ACXP Stock Chart & Stats
$1.46
$0.01(0.70%)
At close: 4:00 PM EDT
$1.46
$0.01(0.70%)
Day’s Range― - ―
52-Week Range$1.07 - $7.54
Previous CloseN/A
Volume25.68K
Average Volume (3M)88.32K
Market Cap
$6.12M
Enterprise Value-$4.05M
Total Cash (Recent Filing)$10.66M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.46
Next Earnings
Nov 18, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding5,559,405
10 Day Avg. Volume88,004
30 Day Avg. Volume88,323
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio-0.55
Enterprise Value/Market Cap-0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.54
Forecast
1Y Price Target
$17.00Price Target Upside1064.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.62
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Pathway ProgressFDA engagement creates a clearer potential registration pathway for ibezapolstat than the company had previously disclosed. Acceptance of PATHFINDER as supportive evidence could improve development efficiency, although eventual progress still depends on robust, consistent clinical results.
Funded Recurrent CDI TrialA fully funded trial with a defined enrollment timeline provides near-term clinical execution visibility and an opportunity to generate registration-relevant evidence. Progress in recurrent CDI could strengthen the asset’s strategic value and support future financing or partnering discussions.
Intellectual Property ProtectionBroad patent coverage across the United States and multiple international markets can protect ibezapolstat’s potential commercial position and support licensing leverage. The additional recurrence and microbiome-related patent expands protection around differentiated clinical and product claims.
Bears Say
Pre-revenue Operating ModelThe absence of product revenue means Acurx cannot currently fund operations through customers or commercial sales. Persistent losses also leave future value dependent on clinical progress, regulatory approval, and eventual commercialization or partnering success rather than an established earnings base.
Funding And Runway RiskThe company can advance PATHFINDER, but the larger pivotal ASPIRE trial requires substantial additional financing that is not secured. This creates a durable execution risk: delays in fundraising or partnering could slow development and postpone the potential regulatory pathway.
Potential Shareholder DilutionRecent equity issuance and sizable warrants show that external capital is being raised through instruments that can expand the share base. Further dilution could reduce existing holders’ proportional ownership and may remain a funding constraint while the company is pre-revenue.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $1.07 and its highest was $7.54 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $6.12M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 29 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Aug 14, 2026. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.377 by -$0.153.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 5,559,405 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.377. Following the earnings report the stock price went down -5.743%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
ACXP Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful regulatory, scientific and IP progress (FDA engagement on a potential single pivotal Phase III pathway, trademark allowance for Syfbezi, fully funded PATHFINDER, manufacturing readiness, partnerships, and strengthened cash vs year-end) while also highlighting material challenges: the need to secure substantial funding to run a large international Phase III (ASPIRE), a limited stated runway (~1 year), rising R&D costs tied to trial startup, ongoing operating losses, and potential dilution from financings. On balance the call emphasized significant program and regulatory momentum but also clear near-term financing and execution risks.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$17.00
▲(1064.38% Upside)
Technical Analysis
Soligenix
―
GeoVax Labs
―
Cocrystal Pharma
―
Citius Pharmaceuticals
―
Aligos Therapeutics
―
Ownership Overview
42.84%
Insiders
0.82% Mutual Funds
0.25% Other Institutional Investors
55.53% Public Companies and
Individual Investors